Inflammatory Bowel Disease
AI shows promise in diagnosis, treatment of IBD, but limitations, concerns remain
Artificial intelligence has been used in various ways to benefit patients with inflammatory bowel disease, with one of the main applications being the prediction and diagnosis of disease.
‘Three-way interaction’ found between HLA-B27, male sex, sacroiliitis development in IBD
CHICAGO — In patients with inflammatory bowel disease, a “strong and consistent three-way interaction” was identified between HLA-B27, male sex and the development of sacroiliitis, according to data presented at Digestive Disease Week.
More JAK inhibitors ‘coming down the pike’ despite poor understanding of mechanism
The pipeline of Janus kinase inhibitors is robust even as researchers struggle to fully understand how they work, according to a presenter at the 2023 Biologic Therapies Summit.
Frequent antibiotic use, diet rich in sweets, urban living heighten risk for pediatric IBD
CHICAGO — A diet rich in sweetened candy or drinks, exposure to antibiotics during early childhood and urban living were among risk factors for developing pediatric inflammatory bowel disease, according to data at Digestive Disease Week.
Colonoscopy withdrawal time of 15 minutes boosts polypoid dysplasia detection in IBD
CHICAGO — Colonoscopy withdrawal time was independently associated with polypoid dysplasia detection in patients with inflammatory bowel disease, with a cutoff time of at least 15 minutes linked to increased odds for detection.
Adalimumab plus methotrexate lowers treatment failure 2-fold in pediatric Crohn’s
Combination therapy with adalimumab plus low-dose methotrexate induced a two-fold reduction of treatment failure among pediatric patients with Crohn’s disease, according to research published in Gastroenterology.
Subcutaneous infliximab could ‘transform’ how patients with IBD navigate care
Subcutaneous infliximab achieved greater clinical remission and endoscopic response rates compared with placebo in patients with inflammatory bowel disease and has potential to become a more convenient, “patient-centric” treatment option.
FDA rejects Eli Lilly’s mirikizumab for ulcerative colitis, citing manufacturing concerns
The FDA issued a complete response letter to Eli Lilly indicating it cannot approve the company’s biologic license application seeking approval for mirikizumab as a treatment for ulcerative colitis.
Q&A: IBD Passport aims to tackle ‘unique barriers’ for travelers with Crohn’s, UC
Travel may no longer be daunting for patients with inflammatory bowel disease, thanks to a “one-stop travel advice” website that offers key resources, support and access to a comprehensive network of IBD specialists worldwide.
TNF inhibitors ‘not always’ standard of care in spondyloarthritis
SCOTTSDALE, Ariz. — Although TNF inhibitors can work “across the spectrum” in spondyloarthritis, they are “not always” the standard of care, according to a presenter at the Basic and Clinical Immunology for the Busy Clinician symposium.